Large variations in biomarker expression was observed across nEVs isolated from the three breast cancer lines, notably with modest CD9 and CD63 expression, abundant CD24 and CD44 expression, practically negligible EpCAM, and moderate HER2 expression levels. This evidence concerns the gene ERBB2 and breast cancer.